Summary
Background
Aim
Methods
Findings
Conclusion
Keywords
Introduction
World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Available at: https://covid19.who.int/[last accessed March 2021].
Methods
Study design and participants
Data collection
Definitions
Centers for Disease Control and Prevention/NHSN. Surveillance definitions for specific types of infections 2020. Available at: https://portaldeboaspraticas.iff.fiocruz.br/wp-content/uploads/2020/10/17pscNosInfDef_current.pdf [last accessed November 2020].
Guidelines Assistance for COVID-19, FHEMIG 2021. Available at: http://www.fhemig.mg.gov.br/index.php?preview=1&option=com_dropfiles&format=&task=frontfile.download&catid=1440&id=14569&Itemid=1000000000000 [last accessed March 2021].
Statistical analyses
Results
Clinical characteristics


Pathogen isolation and mortality risk considering COVID-19 risk factors
Comorbidity/risk factor | Total (negative/positive culture) | OR (95% CI) | P-value | R2 | |
---|---|---|---|---|---|
Discharged | Death | ||||
Cardiovascular disease (N = 136) | 62 (52/10) | 74 (23/51) | 11.53 (4.99–26.63) | <0.0001 | 0.28 |
Diabetes (N = 82) | 38 (28/10) | 44 (14/30) | 6.00 (2.29–15.69) | 0.0002 | 0.17 |
Obesity (N = 56) | 18 (12/06) | 38 (10/28) | 5.60 (1.66–18.92) | 0.0042 | 0.15 |
Invasive ventilation (N = 114) | 24 (14/10) | 90 (25/65) | 3.63 (1.14–11.49) | 0.0005 | 0.07 |
Asthma (N = 23) | 11 (8/03) | 12 (5/7) | 3.73 (0.65–21.58) | 0.1500 | 0.10 |
COPD (N = 7) | 03 (1/02) | 04 (2/2) | 0.5 (0.02–11.09) | 0.6830 | 0.03 |
HIV (N = 8) | 04 (2/2) | 04 (0/4) | Undefined | 0.1266 | 0.33 |
Hypothyroidism (N = 6) | 04 (3/1) | 02 (0/2) | Undefined | 0.1138 | 0.50 |
Influence of secondary pathogen isolation on biochemical and haematological parameters
Parameter | Positive culture | P-value | |
---|---|---|---|
No (N = 123) | Yes (N = 89) | ||
Serum creatinine concentration (mg/dL) | 1.53 ± 1.85 | 2.40 ± 1.85 | <0.0001 |
Leucocyte count (/mm³) | 10,705 ± 8434 | 14,429 ± 7357 | <0.0001 |
Urea (mg/dL) | 60.66 ± 49.28 | 113.7 ± 52.25 | <0.0001 |
C-reactive protein (CRP) (mg/L) | 113.9 ± 98.76 | 159.6 ± 99.18 | 0.0002 |
Haemoglobin concentration (g/dL) | 12.53 ± 2.01 | 11.23 ± 2.31 | <0.0001 |
Platelet count (/mm³) | 268,233 ± 109,669 | 248,012 ± 118,474 | 0.1112 |
Lactate concentration (mmol/L) | 1.53 ± 1.13 | 1.59 ± 1.05 | 0.4979 |
Aetiological agents of coinfections
Patient | Sex | Pathogen, site of isolation | Antibacterial | Antifungal |
---|---|---|---|---|
1 | M | Pseudomonas aeruginosa, TA | CEF, VAN, POL, AMO, CLA, DOX | |
2 | M | Candida tropicalis, TA; Klebsiella pneumoniae, blood, mini-BAL; Staphylococcus aureus, CT | CEF, AZI, MER, VAN, POL, AMI, TIG, SUL | MIC |
3 | M | Candida albicans, TA | CEF, MER, VAN, POL | |
4 | F | Candida albicans, urine; Pseudomonas fluorescens, TA; Candida glabrata, urine | MER, VAN, POL | FLU |
5 | M | Candida albicans, TA | MER, VAN, TAZ | |
6 | F | Candida albicans, urine; Pseudomonas fluorescens, TA | CEF, MER, VAN, POL, AMI | MIC |
7 | F | Candida glabrata, TA, urine | MER, VAN, POL, TAZ | |
8 | F | Stenotrophomonas maltophilia, TA; Staphylococcus aureus, blood, TA; Pseudomonas aeruginosa, TA; Staphylococcus NC, blood | CEF, AZI, VAN, POL, AMO | |
9 | F | Pseudomonas spp., TA; Candida tropicalis, blood | CEF, MER, VAN, POL, CLA | |
10 | F | Candida tropicalis, urine | CEF, AZI, TAZ, CLA, TET | |
11 | F | Candida albicans, urine | CEF, AZI, VAN, COL, CEP, | |
12 | M | Enterobacter spp., TA | CEF, AZI, MER, VAN, CLA, COL | |
13 | M | Klebsiella pneumoniae, blood, TA | CEF, AZI, MER, VAN, POL, COL | |
14 | M | Aspergillus spp., sputum | CEF, AZI, MER, CLI, SUL | |
15 | M | Candida albicans, urine; Acinetobacter baumannii, TA; Klebsiella pneumoniae, CT; Staphylococcus aureus, blood; Staphylococcus NC, CT | CEF, MER, VAN, POL, CLA, LEV, | MIC |
16 | M | Staphylococcus NC, blood; Candida albicans, TA; Aspergillus spp., TA; Candida parapsilosis, TA | CEF, AZI, VAN, POL | |
17 | F | Staphylococcus NC, blood, CT | CEF, MER, VAN, POL, CLA | AMB |
18 | F | Candida albicans, TA | CEF, AZI, MER, VAN, POL, LEV | |
19 | F | Acinetobacter baumannii, TA, CT; Candida glabrata, urine; Candida tropicalis, TA; Staphylococcus NC, blood, CT; Stenotrophomonas maltophilia, TA; Enterococcus spp., blood | CEF, AZI, MER, VAN, POL, TAZ, | MIC |
20 | M | Candida tropicalis, TA | CEF, AZI | |
21 | M | Pseudomonas aeruginosa, TA, blood | CEF, AZI, MER, VAN, POL, AMO, | |
22 | F | Stenotrophomonas maltophilia, TA; Acinetobacter spp., TA | CEF, AZI, MER, VAN, POL, LEV | |
23 | M | Pseudomonas aeruginosa, TA | CEF, AZI, MER, VAN, POL | |
24 | F | Acinetobacter baumannii, TA, CT; Candida albicans, TA; Candida glabrata, urine; Pseudomonas aeruginosa, urine; Candida tropicalis, urine | CEF, AZI, MER, VAN, POL, CEP | |
25 | F | Pseudomonas aeruginosa, urine | CEF, AZI, MER, VAN, TAZ | |
26 | F | Acinetobacter baumannii, TA | CEF, AZI, MER, VAN, LEV, COL, SUL | FLU |
27 | F | Staphylococcus NC, CT; Candida albicans, TA | CEF, AZI, MER, VAN, POL | MIC |
28 | F | Acinetobacter baumannii, TA, CT | CEF, AZI, MER | FLU |
29 | M | Acinetobacter baumannii, TA; Klebsiella pneumoniae, blood, TA | CEF, MER, VAN, POL, CLA, AMI, | FLU |
30 | F | Pseudomonas aeruginosa, TA; Candida tropicalis, TA | CEF, AZI, VAN, AMI | |
31 | M | Pseudomonas aeruginosa, TA; Enterobacter sakasakii, TA; Stenotrophomonas maltophilia, TA | CEF, MER, VAN, POL, CLA, COL, | |
32 | F | Candida albicans, TA; Staphylococcus NC, blood | MER, VAN, POL, TAZ | |
33 | F | Acinetobacter spp., TA; Staphylococcus aureus, TA | CEF, AZI, MER, VAN, POL, COL, | |
34 | M | Candida albicans, sputum | CEF, AZI | |
35 | F | Candida albicans, TA; Acinetobacter baumannii, TA; Staphylococcus aureus, TA; Enterobacter aerogenes, TA | AZI, VAN, POL, TAZ | |
36 | M | Staphylococcus NC, blood, CT; Stenotrophomonas maltophilia, blood; Acinetobacter baumannii, TA | CEF, AZI, VAN, CLA, COL | |
37 | M | Pseudomonas aeruginosa, TA | CEF, VAN, POL, CLA | |
38 | M | Candida albicans, TA; Pseudomonas spp., TA; Candida tropicalis, TA | AZI, MER, CLA, SUL | |
39 | M | Staphylococcus aureus, TA; Stenotrophomonas maltophilia, TA | CEF, AZI, MER, VAN, POL | |
40 | M | Candida tropicalis, TA | CEF, AZI, MER, VAN, POL, | MIC |
41 | M | Candida albicans, sputum; Aspergillus spp., sputum | AZI, AMO | |
42 | F | Candida albicans, TA; Acinetobacter baumannii, TA | CEF, AZI, MER, VAN, POL, | |
43 | M | Pseudomonas aeruginosa, TA; Acinetobacter baumannii, CT | CEF, AZI, VAN, POL, | |
44 | F | Acinetobacter baumannii, TA; Candida albicans, urine | CEF, AZI, MER, VAN, POL, | MIC |
45 | M | Enterococcus spp., CT; Stenotrophomonas maltophilia, TA; Candida albicans, CT, sputum, urine; Staphylococcus NC, CT; Pseudomonas aeruginosa, CT, TA; Acinetobacter baumannii, TA | MER, VAN, POL, COL, AMP, AMI, SUL | MIC |
46 | M | Enterobacter spp., TA | CEF, VAN, CLA | |
47 | M | Candida albicans, TA | CEF, VAN, POL, CLA | |
48 | M | Candida albicans, TA | MER, VAN, POL | |
49 | M | Staphylococcus NC, CT | CEF, MER, VAN, POL | |
50 | M | Candida glabrata, TA; Acinetobacter baumannii, TA | MER | MIC |
51 | M | Pseudomonas aeruginosa, TA | CEF, AZI, VAN, POL | |
52 | M | Aspergillus spp., TA; Candida albicans, TA | CEF, AZI, VAN, POL | |
53 | M | Enterococcus spp., CT, TA; Candida albicans, TA; Klebsiella pneumoniae, blood, TA; Enterobacter spp., TA | CEF, AZI, MER, VAN, POL, COL, AMI, | |
54 | M | Staphylococcus NC, CT | CEF, AZI, MER, VAN, POL, COL | |
55 | M | Acinetobacter baumannii, TA; Candida albicans, urine; Pseudomonas aeruginosa, TA | CEF, AZI, MER, VAN, POL, | |
56 | M | Staphylococcus aureus, blood, TA; Candida albicans, urine; Staphylococcus NC, CT; Enterococcus spp., urine | CEF, AZI, POL, TEI | |
57 | M | Pseudomonas aeruginosa, TA | CEF, AZI, VAN, POL, AMI, TIG | |
58 | F | Staphylococcus aureus, CT; Stenotrophomonas maltophilia, TA; Staphylococcus NC, CT | CEF, AZI, MER, VAN, POL, SUL | MIC |
59 | F | Candida albicans, urine | AZI, AMO, | |
60 | F | Candida albicans, TA; Staphylococcus NC, blood | CEF, AZI, AMO | FLU |
61 | M | Staphylococcus NC, CT; Stenotrophomonas maltophilia, TA; Candida tropicalis, urine | CEF, AZI, MER, VAN, POL, AMI, OXA, SUL | |
62 | F | Candida albicans, TA | CEF, AZI, VAN | |
63 | F | Candida albicans, TA | CEF, AZI, MER, VAN, POL, COL | |
64 | F | Candida kefir, urine; Acinetobacter baumannii, TA | CEF, AZI, MER, VAN, POL, AMO | FLU |
65 | F | Candida tropicalis, TA; Pseudomonas fluorescens, TA | CEF, AZI, VAN, POL | |
66 | F | Staphylococcus NC, CT; Klebsiella aerogenes, TA; Candida albicans, TA; Candida glabrata, TA | CEF, AZI, MER, COL | |
67 | F | Acinetobacter baumannii, blood, TA, CT; Candida tropicalis, urine | ||
68 | F | Candida albicans, urine | AZI, AMO | |
69 | F | Staphylococcus aureus, blood, TA; Klebsiella spp., TA | CEF, AZI, VAN, POL | |
70 | F | Acinetobacter baumannii, TA | CEF, AZI, VAN, POL | |
71 | M | Staphylococcus NC, blood; Klebsiella oxytoca, TA; Klebsiella aerogenes, TA; Escherichia coli, TA | CEF, AZI, VAN, POL | FLU |
72 | F | Acinetobacter baumannii, CT, TA; Staphylococcus NC, CT | CEF, AZI, VAN, POL, CEP | |
73 | F | Klebsiella pneumoniae, TA | CEF, AZI, MER, VAN, POL | |
74 | M | Enterococcus sp., CT, TA; Staphylococcus NC, CT | CEF, AZI, MER, VAN, POL | MIC |
75 | M | Candida albicans, TA | CEF, AZI, MER, VAN, POL | |
76 | F | Acinetobacter baumannii, TA; Candida albicans, TA | CEF, AZI, MER, VAN, POL, TAZ, COL | |
77 | F | Candida albicans, TA | AZI, AMP | |
78 | M | Staphylococcus aureus, blood, TA; Acinetobacter baumannii, TA, urine; Klebsiella aerogenes, TA; Staphylococcus, NC, CT; Enterobacter gergoviae, TA | CEF, AZI, MER, VAN, | MIC |
79 | M | Klebsiella pneumoniae, TA | MER, VAN, POL, TAZ, AMI, TET | |
80 | F | Candida glabrata, blood, CT, refluid, urine; Candida tropicalis, TA | CEF, MER, VAN, POL, CLA, LEV | FLU |
81 | F | Staphylococcus aureus, TA | CEF, VAN, POL, CLA | |
82 | M | Candida glabrata, urine; Candida tropicalis, urine | MER, POL, TAZ, CLA | FLU |
83 | M | Candida albicans, urine, CT; Enterococcus faecalis, CT | CEF, AZI, VAN, POL, CLI | |
84 | M | Pseudomonas aeruginosa, TA | CEF, AZI, VAN, POL | |
85 | M | Candida albicans, CT | MER, VAN, POL | FLU |
86 | M | Staphylococcus aureus, TA; Candida albicans, blood; Pseudomonas aeruginosa, TA | CEF, VAN, POL, CLA | |
87 | M | Klebsiella aerogenes, urine | CEF, CLA | |
88 | M | Candida albicans, TA; Staphylococcus NC, CT | CEF, AZI, MER, VAN, POL, CEP | MIC |
89 | F | Candida tropicalis, urine; Staphylococcus NC, CT | CEF, AZI, MER, VAN, POL, TAZ, AMI, TIG, SUL | MIC |
Genus | OR (95% CI) | P-value |
---|---|---|
Staphylococcus spp. | ||
Staphylococcus NC | 25.40 (3.35–192.66) | <0.0001 |
Staphylococcus aureus | 10.72 (1.35–85.32) | 0.0060 |
Acinetobacter spp. | 6.88 (1.96–24.11) | 0.0007 |
Pseudomonas spp. | 4.77 (1.55–14.70) | 0.0033 |
Enterobacter spp. | 5.10 (0.58–44.40) | 0.1032 |
Klebsiella spp. | 3.06 (0.60–15.52) | 0.1582 |
Enterococcus spp. | Undefined | 0.0141 |
Stenotrophomonas spp. | Undefined | 0.0024 |
Escherichia spp. | Undefined | 0.3219 |
Candida spp. | ||
Candida non-albicans | 11.12 (2.52–49.07) | 0.0001 |
Candida albicans | 3.97 (1.77–8.87) | 0.0004 |
Aspergillus spp. | 1.98 (0.18–22.18) | 0.5729 |
Site of pathogen isolation and risk of death
Site of pathogen isolation | Death (%) | OR (95% CI) | P-value |
---|---|---|---|
Bacteria | |||
Blood (N = 19) | 94.74 | 21.03 (2.75–160.71) | 0.0001 |
Tracheal aspirate (N = 45) | 88.89 | 11.94 (4.49–31.81) | 0.0000 |
Urine (N = 4) | 50.00 | 0.98 (0.14–7.10) | 0.9848 |
Catheter tip (N = 21) | 100 | Undefined | 0.0000 |
Mini-BAL (N = 1) | 100 | Undefined | 0.3219 |
Fungi | |||
Tracheal aspirate (N = 33) | 84.85 | 7.09 (2.62–19.20) | 0.0000 |
Urine (N = 23) | 82.61 | 5.45 (1.78–16.63) | 0.0011 |
Sputum (N = 3) | 33.33 | 0.48 (0.04–5.44) | 0.5508 |
Catheter tip (N = 4) | 100 | Undefined | 0.0460 |
Blood (N = 4) | 100 | Undefined | 0.0460 |
Refluid (N = 1) | 100 | Undefined | 0.3218 |
Discussion
- Clark A.
- Jit M.
- Warren-Gash C.
- Guthrie B.
- Wang H.H.X.
- Mercer S.W.
- et al.
Conflict of interest statement
Funding sources
References
World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Available at: https://covid19.who.int/[last accessed March 2021].
- Treatment for COVID-19: an overview.Eur J Pharmacol. 2020; 889: 173644https://doi.org/10.1016/j.ejphar.2020.173644
- Coinfections in people with COVID-19: a systematic review and meta-analysis.J Infect. 2020; 81: 266-275https://doi.org/10.1016/j.jinf.2020.05.046
- Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.JAMA Intern Med. 2020; 180: 934-943
- Why is coinfection with influenza virus and bacteria so difficult to control?.Discov Med. 2015; 19: 33-40
- Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing.Clin Infect Dis. 2020; 71: 2459-2468
- Clinical characteristics of COVID-19 in New York City.N Engl J Med. 2020; 382: 2372-2374
- Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.JAMA. 2020; 323: 1061-1069
- High prevalence of putative invasive pulmonary aspergillosis in critically ill COVID-19 patients.Resp Med. 2020; 8: E48-E49https://doi.org/10.1016/S2213-2600(20)30237-X
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet. 2020; 395: 507-513https://doi.org/10.1016/S0140-67362030211-7
- Bacterial and viral coinfections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU.Ann Intens Care. 2020; 10: 119https://doi.org/10.1186/s13613-020-00736-x
- Clinical spectrum of SARS-CoV-2 infection.2020 (Available at:) ([last accessed September 2020])
Centers for Disease Control and Prevention/NHSN. Surveillance definitions for specific types of infections 2020. Available at: https://portaldeboaspraticas.iff.fiocruz.br/wp-content/uploads/2020/10/17pscNosInfDef_current.pdf [last accessed November 2020].
Guidelines Assistance for COVID-19, FHEMIG 2021. Available at: http://www.fhemig.mg.gov.br/index.php?preview=1&option=com_dropfiles&format=&task=frontfile.download&catid=1440&id=14569&Itemid=1000000000000 [last accessed March 2021].
- Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data.Lancet Respir Med. 2021; 15: S2213-S2600https://doi.org/10.1016/S2213-2600(20)30560-9
- Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission.Nat Commun. 2020; 11: 6317https://doi.org/10.1038/s41467-020-19741-6
- Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study.Lancet Glob Health. 2020; 8: e1003-e1017https://doi.org/10.1016/S2214-109X(20)30264-3
- Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a retrospective cohort study of patients with and without COVID-19.EClinicalMedicine. 2020; 27: 100518
- COVID-19 and multiorgan response.Curr Probl Cardiol. 2020; 45: 100618
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet. 2020; 395: 497-506https://doi.org/10.1016/S0140-6736(20)30183-5
- Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.Nat Rev Immunol. 2020; 20: 355-362https://doi.org/10.1038/s41577-020-0331-4
- Bacterial and fungal infections in COVID-19 patients: a matter of concern.Infect Control Hosp Epidemiol. 2020; 41 (httpps://doi:10.1017/ice.2020.156): 1124-1125
- COVID-19 and the clinical hematology laboratory.Int J LabHematol. 2020; 42: 11-18
- Staphylococcus epidermidis – the ‘accidental’ pathogen.Nat Rev Microbiol. 2009; 7: 555-567https://doi.org/10.1038/nrmicro2182
- Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.Clin Microbiol Infect. 2020; 26: 1622-1629https://doi.org/10.1016/j.cmi.2020.07.016
- SARS-CoV-2, bacterial coinfections, and AMR: the deadly trio in COVID-19?.EMBO Mol Med. 2020; 12e12560
- Fungal infections should be part of the core outcome set for COVID-19.Lancet Infect Dis. 2020; 7: S1473-S3099
- EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units.JAMA. 2009; 302: 2323-2329
- Candida pneumonia in intensive care unit? Open Forum Infect Dis. 2014; 1: ofu026